Our results show that ponatinib is highly effective on both sensitive and resistant CML cell lines, whatever the mode of resistance and also on BaF3 murine B cells carrying native BCR-ABL or T315I mutation. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.